Possible Prognostic Benefit from ABMT in First Remission Adult Acute Lymphoblastic Leukemia
We analyzed the long-term results of a phase II trial closed in 1993, including ABMT (autologous bone marrow transplant) with post-graft chemotherapy as consolidation therapy for first remission adult ALL patients. Seventy-nine patients in remission after ‘IVAP’ (idarubicin-vincristine-L-asparaginase-prednisone) were to receive 4 consolidation cycles followed by marrow harvest (unpurged), cranial irradiation, and ABMT after BCNU 300 mg/m2, etoposide 900 mg/m2, and melphalan 110 mg/m2 (restricted to patients 15–50 years-old). The ABMT regime was intentionally of „limited“ intensity, to minimize the risks of toxic death and to resume promptly continuation therapy with alternate drug pairs for 12 weeks and low-dose maintenance with mercaptopurine and methotrexate for 6 mos. (ABMT) or 18 mos. (no ABMT). At the end of early consolidation 67 patients were alive and still in CR: 10 underwent an allogeneic BMT, 32/47 aged <50 years had an ABMT, and 10 aged >50 years had chemotherapy without transplants. Long-term disease-free survival was positively affected by the following variables: age <35 years /blast count <25×109/l (P<0.001), good treatment realization score (P<0.001), t(9:22)/BCR-ABL negativity (P<0.01), allogeneic BMT and ABMT (P P<0.01, P<0.005), and pre-B CD10+ phenotype (P<0.05). The 5-year DFS rate was 73% for standard-risk patients (age <35, blast count <25×109/l, and Ph/BCR negativity) receiving treatment without major alterations/attenuation and therefore including ABMT in most instances (P<0.001). However, the prognosis of high-risk cases was uniformly poor. This analyis suggested a possible prognostic benefit from ABMT followed by further chemotherapy in standard-risk adult ALL. However, because treatment was scarcely effective in high-risk ALL and good DFS results can be obtained without ABMT in standard-risk cases, the exact role of this therapeutic procedure in specific risk classes remains undetermined.
KeywordsAutologous Bone Marrow Blast Count Prognostic Benefit Complete Remission Patient Early Consolidation
Unable to display preview. Download preview PDF.
- 7.Attal et al. (1995) Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 86:1619–1628PubMedGoogle Scholar
- 9.Kantarajian et al. (1990) Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8:994–1004Google Scholar
- 10.Fayad et al. (1996) Significance of day 7 (D7) persistence of peripheral blasts (PBb) >0, and day 14 (D14) persistence of bone marrow blasts (BMb) >5% in adult acute lymphocytic leukemia (ALL) according to treatment intensity. Blood 88 (suppl 1): 374aGoogle Scholar
- 12.Singhal et al. (1997) Sequential high-dose therapy of acute lymphoblastic leukemia in adult patients: long term follow-up. Blood 90 (suppl 1): 253aGoogle Scholar
- 13.Hoelzer et al. (1993) Results of intensified consolidation therapy in four consecutive german multicentre studies for adult ALL. Blood 82 (suppl 1): 193aGoogle Scholar
- 17.Lerede et al. (1998) Prolonged remission in adult B-ALL (L3) and advanced Burkitt’s lymphoma using acute leukemia regimens: study of 34 patients. In: Hiddemann W, Buchner T, Wormann B, Ritter J, Creutzig U, Keating M, Plunkett W (eds) Acute leukemias VII, Springer-Verlag, Berlin, PP 783–789Google Scholar
- 20.Camara et al. (1998) Bone marrow transplantation in acute lymphoblastic leukemia (ALL): comparison of busulfan versus total body irradiation (TBI) as conditioning. Bone Marrow Transplant 21 (suppl 1): 359a.Google Scholar